GLP-1 receptor agonist sales will grow through 2036, led by exenatide at 24.4% share of the drug segment in 2025. Diabetes leads the indication segment as physicians continue prescribing GLP-1 therapies. The market is expected to reach USD 2.9 billion in 2026 and USD 7.8 billion by 2036.